Table 2.

Sensitivity of imaging^*

Imaging method	Nonmetastatic primary PPGL		Metastases		Primary head and neck PGL
	No. positive/No. of tumors	% (95% CI)	No. positive /No. of tumor regions	% (95% CI)	No. positive/No. of tumors	% (95% CI)
18F-FDG PET†	53/69	76.8 (66.6 to 87.0)	170/206	82.5 (77.3 to 87.8)	18/26	69.2 (50.2 to 88.2)
123I-MIBG SPECT‡	48/64	75.0 (64.1 to 85.9)	86/172	50.0 (42.5 to 57.6)	7/21	33.3 (11.4 to 55.3)
CT/MRI	66/69	95.7 (90.7 to 100.6)	148/199	74.4 (68.3 to 80.5)	N/A	N/A

^*Sensitivities are expressed as the number of positive body regions/the total number of tumor-positive regions, with percentages and 95% CIs. CI = confidence interval; CT/MRI = computed tomography with magnetic resonance imaging; ¹⁸F-FDG PET = [¹⁸F]-fluorodeoxyglucose positron emission fluorography; ¹²³I-MIBG SPECT = [¹²³I]-metaiodobenzylguanidine single photon emission computed tomography; N/A = not applicable; PPGL = pheochromocytoma and paraganglioma.

^†For nonmetastatic primary PPGL; ¹⁸F-FDG vs ¹²³I-MIBG ns, FDG vs CT/MRI P < .001; within metastases; ¹⁸F-FDG vs ¹²³I-MIBG P < .001, FDG vs CT/MRI P = .08; within primary head and neck PGL; ¹⁸F-FDG vs ¹²³I-MIBG P = .031 (McNemar test, two-sided).

^‡For nonmetastatic primary PPGL; ¹²³I-MIBG vs CT/MRI P = .002; within metastases; ¹²³I-MIBG vs CT/MRI P < .001 (McNemar test, two-sided).